Marked increase in gastric acid secretory capacity after omeprazole treatment

Gut

Volumn 39, Issue 5, 1996, Pages 649-653

  Waldum, H L ^a   Arnestad, J S ^b   Brenna, E ^b   Eide, I ^b   Syversen, U ^b   Sandvik, A K ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Acid related diseases; Acid secretion; Gastrin; Histamine; Proton pump inhibitors

Indexed keywords

CHROMOGRANIN A; GASTRIN; HISTAMINE; OMEPRAZOLE; PROTON PUMP; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTEROCHROMAFFIN CELL; FEMALE; HUMAN; HYPERGASTRINEMIA; MALE; PRIORITY JOURNAL; REBOUND; STOMACH ACID SECRETION;

EID: 0030468499     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.5.649     Document Type: Article

References (40)

1. Blair AJ, Richardson CT, Walsh JN, Feldman M. Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology 1987; 92: 944-9.
2. Sandvik AK, Waldum HL, Kleveland PM, Schulze Søgnen B. Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol 1987; 22: 803-8.
3. Brenna E, Waldum HL. Studies of isolated parietal and enterochromaffin-like cells from the rat. Scand J Gastroenterol 1991; 26: 1295-306.
4. Prinz C, Kajimura M, Scott DR, Mercier F, Helander HF, Sachs G. Histamine secretion from rat enterochromaffin-like cells. Gastroenterology 1993; 105: 459-61.
5. Waldum HL, Sandvik AK, Brenna E, Schulze Søgnen B. Radioimmunoassay of histamine. Scand J Gastroenterol 1991; 26 (suppl 180): 32-9.
6. Leth R, Olbe L, Haglund U. The pentagastrin-induced gastric acid response in humans. Scand J Gastroenterol 1988; 23: 224-48.
7. Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrinhistamine sequence in the regulation of gastric acid secretion. Gut 1991; 32: 698-701.
8. Ryberg B, Tielemans Y, Axelson J, Carlsson E, Håkanson R, Mattson H, et al. Gastrin stimulates the selfreplication rate of enterochromaffin-like cells in the rat stomach. Gastroenterology 1990; 99: 935-42.
9. Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut 1992; 33: 1303-6.
10. Sjöblom S-M, Sipponen P, Karonen S-L, Järvinen HJ. Argyrophil cell hyperplasia and carcinoid tumours in oxyntic mucosa of the stomach. Dependence on duration of pernicious anaemia. Eur J Gastroenterol Hepatol 1991; 31: 153-7.
11. Waldum HL, Sandvik AK, Syversen U, Brenna E. The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role. Acta Oncol 1993; 32: 141-7.
12. Kleveland PM, Waldum HL, Larsson H. Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion. Scand J Gastroenterol 1987; 22: 705-13.
13. Waldum HL, Sandvik AK. Histamine and the stomach. Scand J Gastroenterol 1989; 24: 130-9.
14. Waldum HL, Lehy T, Brenna E, Sandvik AK, Petersen H, Schulze Søgnen B, et al. Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastrin mucosa. Scand J Gastroenterol 1991; 26: 23-35.
15. Larsson H, Carlsson E, Ryberg B, Fryklund J, Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol 1988; 254: G33-9.
16. Lamberts R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 39: 126-35.
17. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux oesophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
18. Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993; 32: 161-5.
19. Savary M, Miller G. The oesophagus. Solothurn: Gassmann, 1977.
20. Lorenz W. Histamine release in man. Agents Actions 1975; 5: 402-16.
21. Morel AM, Delaage MA. Immunoanalysis of histamine through a novel chemical derivatization. J Allergy Clin Immunol 1988; 82: 646-54.
22. Maeland JA, Kleveland PM, Neass AI. Contribution of antibodies reacting with Campylobacter jejuni antigens in the testing of human sera for anti-Helicobacter pylori antibodies. Serodiagnosis and immunotherapy in infectious disease 1993; 1: 32-6.
23. Syversen U, Jacobsen MB, O'Connor DT, Rønning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994; 26: 201-6.
24. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and toxicology of omeprazole with special reference to the effects on the gastric mucosa. Scand J Gastroenterol 1986; 21 (suppl 18): 31-8.
25. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60-4.
26. Fullarton GM, McLauchlan G, MacDonald A, Crean GP, McColl KEL. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut 1989; 30: 449-54.
27. Sharma BK, Walt RP, Pounder RE, Gomes M de FA, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64.
28. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6.
29. Prewett EJ, Hudson M, Nwokolo CU, Sawyerr AM, Pounder RE. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 1991; 100: 873-7.
30. Creutzfeldt W, Stöckmann F, Conlon JM, Fölsch UR, Bonatz G, Wülfrath M. Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion 1986; 35 (suppl 1): 84-97.
31. Prewett EJ, Smith JTL, Nwokolo CU, Hudson M, Sawyer AM, Pounder RE. Eradication of Helicobacter pylori abolishes 24-hour hypergastrinemia: a prospective study in healthy subjects. Aliment Pharmacol Ther 1991; 5: 283-90.
32. Go VLW, Hofmann AF, Summerskill WHJ. Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology 1970; 58: 321-8.
33. El-Omar E, Penman I, Dorrian CA, Ardill JES, McColl KEL. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993; 34: 1060-5.
34. Waldum HL, Brenna E, Kleveland PM, Sandvik AK. Gastrin - physiological and pathophysiological role: clinical consequences. Dig Dis 1995; 13: 25-38.
35. Tielemans Y, Axelson J, Sundler F, Willems G, Håkanson R. Serum gastrin concentration affects the self-replication rate of the enterochromaffin like cells in the rat stomach. Gut 1990; 31: 274-8.
36. Sundler F, Håkanson R. Gastric endocrine cell typing at the light microscopic level. In: Håkanson R, Sundler F, eds. The stomach as an endocrine organ. Erik Fernstrøm Symposium. Amsterdam: Elsevier, 1991: 9-26.
37. Chen D, Uribe A, Håkanson R, Sundler F. Somatostatin cells in the oxyntic mucosa of hypo- or hypergastrinemic rats. Scand J Gastroenterol 1992; 27: 479-82.
38. Pisegna JR, Norton JA, Slimack GG, Metz DC, Maton PN, Gardner JD, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992; 102: 767-78.
39. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498-508.
40. Saeed ZA, Norton JN, Frank WO, Young MD, Maton PN, Gardner JD, et al. Parietal antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 1989; 96: 1396-402.